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1. Abstract  
     Joint immobilization is a common treatment for musculoskeletal disorders to relieve joint 
pain and decrease inflammation, however it often has a direct effect on joint contracture. The cause 
of joint contracture is divided in arthrogenic and myogenic components. Among these, the joint 
capsule plays an important role in the progression of joint contracture. Joint immobilization 
decreases synovial fluid and hyaluronan (HA) expression levels, and it also causes prolonged 
inflammation, adhesion, and fibrosis of the joint capsule. A number of studies have suggested that 
the use of HA can prevent postoperative adhesions. However, the influence of HA on immobilized 
synovial tissue is still unknown. The purpose of this study was to elucidate preventive effects of 
high molecular weight hyaluronan (HMWHA) on the joint capsule of immobilized knees in rats. 
Unilateral knee joints of rats were immobilized with an internal fixator. Either 50 µl of HMWHA 
(Im-HA group) or 50 µl of saline (control group) was administered intra-articularly once a week 
after surgery. Sagittal sections were prepared from the medial midcondylar region of the knee joints 
and assessed by histological, histomorphometric, and immunohistochemical methods. Gene 
expressions related to inflammation, fibrotic conditions, and hypoxia were evaluated by quantitative 
reverse transcription polymerase chain reaction (qRT-PCR). Tissue elasticity of the capsule from 
both groups was examined using a scanning acoustic microscope (SAM). CD68 positive cells 
decreased in adhesion areas of the synovial membrane (SM) after 1 week in both groups. The length 
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of the superficial layer in the SM of the Im-HA group was significantly longer than those in the 
control group over a period of 4 to 8 weeks with significantly small numbers of CD68 positive cells. 
The gene expressions of IL-6, IL-1β, TGF-β, CTGF, COL1a1, COL3a1, SPARC, and HIF1-α were 
significantly lower in the Im-HA group compared to those in the control group. The sound speed of 
the anterior and posterior SM increased significantly (a reduction in elasticity) in the control group 
compared to those in the Im-HA group during weeks 1 to 4. This study demonstrated that HMWHA 
injections suppressed inflammatory, fibrotic, and hypoxic conditions observed in the immobilized 
joint capsule. 
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2. Introduction 
    Joint immobilization is a common treatment for musculoskeletal disorders to relieve joint pain 
and decrease inflammation, however it often has a direct effect on joint contracture 1). Preventing 
joint contracture has obvious advantages over most therapeutic methods. Joint contracture is 
defined as a limitation of range of motion (ROM) and causes permanent impairment and disability 
of daily living in various aspects 2). The cause of joint contracture is classified into two components: 
arthrogenic (bone, cartilage, synovial membrane, capsule and ligaments) and myogenic (muscle, 
tendon, and fascia) 3). The joint capsule is composed of two distinct layers: an external dense 
fibrous layer (defined as a capsule) and an internal synovial membrane 4). Recent studies indicate 
that arthrogenic factors, especially the joint capsule, play an important role in a progression of 
limited ROM after joint immobilization 3,5-10). In our previous study, elasticity of the joint capsule 
decreased 7) and the ROM was restored after capsular release in an immobilized knee model in rats 
6). 
     Joint contracture can occur in every joint, but the shoulder joint is one of the most affected 
ones. Joint contracture in the shoulder joint is called as frozen shoulder with pain and loss of 
mobility11). The estimated prevalence of frozen shoulders is 2-5% in the general population 12), and 
predominantly women in the 40-70 age group 13). Historically, frozen shoulder is considered to be a 
self-limited disease11) . However, some patients show little or no improvement of limited ROM 
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even after extensive rehabilitation. Patients with no improvement after mobilization and stretching 
can regain satisfactory ROM after an arthroscopic capsular release 14,15), which suggests that the 
joint capsule is one of the main causes of frozen shoulder. 
      As for the pathology of frozen shoulder, Neviaser reported perivascular infiltration with 
inflammatory cells and capsular fibrosis 16). Lundberg described increased collagen density and 
glycosaminoglycan distribution in the capsule of frozen shoulder17). Bunker showed active 
fibroblast proliferation and transformation to myofibroblasts 
18)
, and Hand revealed proliferating 
fibroblasts and chronic inflammatory cells in the capsule from frozen shoulder 
19)
. Rodeo reported 
that the following growth factors such as transforming growth factor-beta (TGF-β), platelet-derived 
growth factor (PDGF), and Inter Leukin-1β (IL-1β) were involved in frozen shoulder
20)
 . In our 
previous study, gene expressions related to fibrosis such as collagen type 1A1 (COL1A1) and 
COL13 A1, chondrogenesis such as FBJ murine osteosarcoma viral oncogene homolog (FOS), FBJ 
murine osteosarcoma viral oncogene homolog B (FOSB), aggrecan (ACAN), and COL10A1, and 
angiogenesis such as Cysteine-rich angiogenic inducer 61 (CYR61) were significantly higher in 
idiopathic frozen shoulder from DNA microarray analysis 8). The joint capsule from the shoulder 
joint was much stiffer in frozen shoulder when compared to those from shoulder with rotator cuff 
tears 8) . 
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     A significant linear decrease in skin blood flow around the shoulder was observed with 
increasing age 21), and skin temperature decreased in frozen shoulder 22,23). In our recent study, poor 
posture, including internal rotation of scapula, decreased blood flow of the anterior circumflex 
artery, which seems to be related to frozen shoulder 24). There might be close relationship between 
ageing, posture and blood supply around the shoulder. Furthermore, in our previous study, patients 
with diabetes mellitus, having vascular fragility, responded worse to conservative treatments of 
frozen shoulder 25). Okuno showed abnormal neovessels, which lead hypoxia for the peripheral 
tissues, at the rotator interval capsule in frozen shoulder and transcatheter arterial embolization is 
effective for these lesions 26). Prolonged ischemia produced more pain with a substantial increase of 
pro-inflammatory mediators 27). These data support that the inflammatory, fibrotic, hypoxic, and 
chondrogenic processes are one of the main pathologies in frozen shoulder. Our predicted pathology 
of frozen shoulder is shown in Figure 1. 
     To investigate the pathology of frozen shoulder as well as joint stiffness in other joints, we 
developed an animal model of immobilized knee in rats. Our previous animal experiments showed 
that joint immobilization induced adhesions and shortening of the synovial membrane 28）, hypoxic, 
inflammatory 29), and fibrotic conditions 30） in the joint capsule, and decreased elasticity of the 
capsule7）. These data seems to correspond well with the frozen shoulder studies of ours.  
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      Joint adhesion formation begins with an inflammatory response and can be regarded as 
tissue fibrosis 31-34). Some growth factors, cytokines, and matrix metalloproteinases might play an 
important role 20,35). It is widely recognized that monocytes, macrophages and neutrophils have 
important roles in the progression and resolution of fibrosis 36). Macrophages are found in close 
proximity with collagen-producing myofibroblasts and indisputably play a key role in fibrosis 37). 
They are major producers of some cytokines, such as PDGF, Tumor Necrosis Factor-α (TNF-α), 
IL-1, Inter Leukin-6 (IL-6), and TGF-β1, which are key drivers of fibrosis 36,37). TGF-β1 is a 
primary cause of profibrotic cytokine that can induce collagen-secreting myofibroblasts in fibrotic 
tissues 36,38). Furthermore, TGF-β1 was shown to stimulate collagen type I synthesis and secreted 
acidic and rich in cysteine (SPARC) expression 38,40). Several studies show that SPARC is closely 
related to various fibrotic diseases 41-43).  
     HA is a high molecular weighing polysaccharide and is an important component of synovial 
fluid and the extracellular matrix of the articular cartilage 44,45). HA acts as a fluid shock absorber, 
which helps to maintain structural and functional characteristics of the cartilage matrix. In addition 
to its function as a passive structural molecule, hyaluronan also acts as a signaling molecule by 
interacting with a cells surface receptors and regulating cell proliferation, migration, and 
differentiation 46-48). It also inhibits the formation and release of prostaglandins, induces 
proteoglycan aggregation and synthesis, modulates the inflammatory response 46,47), and inhibits 
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growth of blood vessels and sensory nerves 48). Joint immobilization decreases HA concentration 
and molecular size in synovial fluid 49,50) and causes advanced osteoarthritis with degeneration 
and/or atrophy of the articular cartilage 51,52). A few studies were reported about HA effects on 
frozen shoulder. Capsular distension with intra-articular HA injection was shown to be a treatment 
method in pain relief and functional improvement 53）. Intra-articular HA injection suppressed 
synovitis in the shoulder joint through an antiinflammatory effect by dynamic magnetic resonance 
imaging enhanced with Gd-DTPA 54）. 
     Although the predominant mechanism of HA is still unknown, in vivo, in vitro, and clinical 
studies demonstrate the various physiological effects of exogenous HA. Intra-articular injections of 
HA have demonstrated a protective effect on the articular cartilage and have widely been used in 
the treatment and prevention of osteoarthritis 55-57)  
     The efficacy of intra-articular HA injections might be dependent on viscoelastic properties 
and a function of its molecular weight in osteoarthritis 58,59). Several studies have shown differential 
effects of high molecular weight HA (HMWHA) and low molecular weight HA (LMWHA) on 
different types of cells such as macrophages, dendritic cells, osteoclasts, and T cells 60,61). HMWHA 
is known to block the CD44 receptor reaction, with hyaluronan oligomers moderating the 
proinflammatory process 62,63). It was suggested that a HMWHA may provide improved clinical 
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benefits of reducing pain 64-66). Lo et al. reported that the HMWHA was more effective for the 
treatment of knee osteoarthritis by a meta-analysis, however, the heterogeneity of the included trials 
limited the validity of such a definitive conclusion 65). Recent studies have found that an 
intra-articular injection of LMWHA decreased adhesion formation as well as collagen content, and 
increased ROM after prolonged immobilization in a rabbit knee injury model 67). However, the 
influence of HMWHA on immobilized joint capsule as well as synovial membrane is still unknown. 
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3. Purpose 
       The purpose of this study was to elucidate preventive effects of HMWHA on the joint 
capsule of immobilized knees in rats. I applied histological, histomorphometric, and 
immunohistochemical techniques to analyze these changes. In addition, I assessed tissue elasticity 
of the capsule using a scanning acoustic microscope (SAM). The gene expressions related to 
inflammatory, fibrotic, and hypoxic conditions were evaluated by quantitative reverse transcription 
polymerase chain reaction (qRT-PCR). I hypothesized that HMWHA injections suppress the 
inflammatory, fibrotic, and hypoxic changes in the capsule after immobilization, prevent adhesion 
and shortening of the synovial membrane, and decrease the elasticity of the synovial membrane and 
capsule. 
 
  
11 
 
4. Materials and Methods 
4.1. Experimental Design and Surgical Procedure 
Animals 
        Protocol for this experiment was approved by the Animal Research Committee of Tohoku 
University. Mature Sprague-Dawley male rats, aged 12 weeks old, were used (CLEA Japan Inc., 
Tokyo, Japan). A total of 84 rats were prepared for histological analysis (1, 2, 4, 6, 8, 12, and 16 
weeks; n = 6/each period). Thirty six rats were prepared for qRT-PCR (1, 2, and 4 weeks; n = 
6/each period). Under anesthesia with intra-peritoneal administration of sodium pentobarbital (50 
mg/kg), the unilateral knee joints were rigidly immobilized at 150 degrees of flexion with a plastic 
plate and metal screws for various periods (1, 2, 4, 6, 8, 12, and 16 weeks: n=6/each period) 68) 
(Fig.2A and B). After the operation, the rats were divided into two groups: Immobilized-HA 
injection (Im-HA) group and immobilized-normal saline injection (Control) group. A shot of 50 µl 
of HA with a high molecular weight of 2700 kDa (Suvenyl ; Chugai Pharmaceutical Co., Ltd., 
Tokyo, Japan) was administered intra-articularly after the surgery for the Im-HA group on the day 
of surgery, and once a week until euthanasia (1, 2, 4, 6, 8, 12, or 16 weeks: n=6/each period). An 
identical amount of normal saline was administered for the Control group 69) (Fig. 2C). 
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4.2. Tissue Preparation 
       At the end of the experimental period, the rats were euthanized with an overdose of sodium 
pentobarbital and fixed with 4% paraformaldehyde in 0.1 M phosphate buffered saline (PBS), pH 
7.4 by perfusion through the ascending aorta. The resected knee joints were kept in the same 
fixative state for 24 hours at 4°C. The fixed specimens were decalcified in 10% 
ethylenediaminetetraacetic acid in 0.01 M PBS for 2 months at 4°C. After dehydration through a 
graded series of ethanol solutions, the specimens were embedded in paraffin. At the medial 
midcondylar region of the knee, 5 µm sections were obtained 7).  
4.3. Histology and Histomorphometry 
         The sections were stained with Hematoxylin and Eosin, and morphological changes of 
the synovial membrane and capsule were observed in the anterior and posterior portion. The length 
of the superficial layer of the synovial membrane of the antero-superior, antero-inferior, 
postero-superior, and postero-inferior capsule, outside length of the posterior capsule, and the 
anterior and posterior capsular areas were measured as previously reported 28) (Fig. 3). 
4.4 Scanning acoustic microscope (SAM) 
  Sound speed of the synovial membrane and capsule was assessed by SAM. In general, 
sound speed is proportional to the square root of Young’s elastic modulus. SAM can measure sound 
speed of tissues on slide glass in situ. It consists of five parts: 1) ultrasonic transducer, 2) pulse 
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generator, 3) digital oscilloscope with PC, 4) microcomputer board and 5) display unit 7,70) (Fig. 4A 
and B). The system of SAM was briefly mentioned as follows; a single pulsed ultrasound with 5 ns 
pulse width was emitted and received by the same transducer above the specimen. The aperture 
diameter of the transducer was 1.2 mm and the focal length was 1.5 mm. The central frequency was 
80 MHz and the pulse repetition rate was 10 kHz. Considering the focal distance and the sectional 
area of the transducer, the diameter of the focal spot was estimated as 20 µm at 80 MHz. Distilled 
water was used as the coupling medium between the transducer and the specimen. The reflections 
from the tissue surface and from interface between the tissue and the glass were received by the 
transducer and were introduced into a digital oscilloscope (Tektronics TDS 5052, USA). The 
frequency range was 300 MHz and the sampling rate was 2.5 GS/s. Four pulse responses at the 
same point were averaged in the oscilloscope in order to reduce random noise. The transducer was 
mounted on an X–Y stage with a microcomputer board that was driven by the computer installed in 
the digital oscilloscope through an RS- 232C. The X-scan was driven by a linear servo-motor and 
the Y-scan was driven by a stepping motor. Finally, two-dimensional distributions of the ultrasonic 
intensity, sound speed and thickness of the 2.4 by 2.4 mm specimen area were visualized with 300 
by 300 pixels. The total scanning time was 121 sec 7). 
A region of analysis was set in the anterior and posterior portion in each section (Fig. 5). In 
the region, the sound speed of the synovial membrane and capsule, excluding meniscus, bone and 
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cartilage, was calculated with a gray scale SAM images using commercially available image 
analysis software (PhotoShop CC 2014, Adobe Systems Inc., San Jose, CA). SAM images with a 
gradation color scale were also produced for clear visualization of the sound speed. The optical and 
acoustic images were compared to ensure morphological congruence in the analysis. 
4.5 Immunohistochemistry (IHC) 
Number of the macrophage and number of blood vessels 
       The sections were deparaffinized and immersed in 3.0 % hydrogen peroxide. The slides for 
Cluster of differentiation 68 (CD68), and Alpha smooth muscle actin (α-SMA), were incubated with 
0.1 % trypsin and 0.1 % CaCl2/Tris buffer. Endogenous immunoglobulins were blocked by 
incubation with normal goat serum (Nichirei, Tokyo, Japan). The slides were incubated with mouse 
anti-rat CD68 antibody (MCA341R, AbD Serotec, Raleigh, NC, dilution 1:400), which was a 
marker of the macrophage-like type A synoviocyte 71) or rabbit polyclonal α-SMA antibody 
(ab5694, Abcam, Cambridge, UK, dilution 1:100), which was a marker for myofibroblasts. 
However, α-SMA was also expressed abundantly in smooth muscle cells of blood vessels and 
pericytes 72). The final detection step was carried out using 3,3’ -diaminobenzidine 
tetrahydrochloride (DAB) (Sigma, St. Louis, MO) in 0.1 M imidazole and 0.03 % H2O2 as the 
chromogen. Counterstaining was done with Carazzi’s haematoxylin. Negative control was 
performed using normal mouse IgG (Dako, Copenhagen, Denmark) as a primary antibody. All 
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slides were stained in one session 28,29). The number of CD68 positive cells in the posterior capsule 
was counted.  
       I divided the capsule into 4 areas, antero-superior, postero-superior, antero-inferior, and 
postero-inferior areas according to our previous report 28) (Fig. 6). Blood vessels were defined as the 
lumen structure with strong immunostaining of α-SMA. The images of blood vessels in each area 
were captured at a magnification of 100× with light microscopy and the number of blood vessels 
was counted. I counted longitudinal profiles in the same way as cross- sectional profiles. The 
number was converted to blood vessels/ mm
2
 as previously described 29). 
Immunohistochemical double staining of CD68/IL-6 
        The sections were deparaffinized and washed in PBS and double stained with IL-6 and 
CD68. After predigestion with elimination of nonspecific binding with 10% normal goat serum 
(Nichirei, Tokyo, Japan), the sections were incubated with a rabbit anti-rat IL-6 antibody (ab6672, 
Abcam, Cambridge, UK, dilution 1:400) and mouse anti-rat CD68 antibody (MCA341R, AbD 
Serotec, Raleigh, NC, dilution 1:400) at 4°C Secondary staining with Alexa-Fluor-488 conjugated 
donkey anti-rabbit (Molecular Probes, Invitrogen) and Alexa-Fluor-594 conjugated goat anti-mouse 
secondary antibodies (Molecular Probes, Invitrogen) were carried out at room temperature for 60 
min, followed by 4',6-Diamidino-2- Phenylindole (DAPI) nuclear counterstaining for 10 min.  
4.6 qRT-PCR 
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        After administration of an overdose sodium pentobarbital, the capsule of the knee was cut 
with a surgical knife and the harvested capsule was immediately placed in a vessel containing 1 ml 
QIAzol (Qiagen, Hilden, Germany) as previously described 68). The tissue was disrupted and 
homogenized with PolytronTM (Kinematica AD, Switzerland). The total RNA of the homogenate 
was purified using RNeasy Lipid Tissue Mini Kit (Qiagen) and complementary DNA (cDNA) was 
synthesized using Cloned AMV First-strand cDNA Synthesis Kit (Invitrogen, Carlsbad, CA). PCR 
efficiencies and relative expression levels of IL-6, IL-1β, Connective Tissue Growth Factor (CTGF), 
TGF-β1, SPARC, collagen type 1 (COL1a1), collagen type 3 (COL3a1), hypoxia inducible 
factor-1α (HIF-1α), and vascular endothelial growth factor (VEGF) as a function of elongation 
factor 1α1 (EF1α1) were calculated as previously described 68). Primer sequences for expression 
analysis were shown in Table 1. The qPCR temperature profile was 3 minutes 95°C initial melt; 20 
seconds 95°C, 30 seconds 58°C for 45 cycles; 30 seconds 95°C for 1 cycle; and 1 minute 55°C 
followed by stepwise temperature increases from 55°C to 95°C to generate the melt curve. Standard 
curves were generated with each primer set with untreated control cDNA and a 10-fold dilution 
series ranging from 1000 ng/ml to 100 pg/ml. 
4.7 Statistical analysis 
        This was an open labeled study. Statistical analysis among the groups was performed 
using one-way ANOVA with Bonferroni/Dunn post hoc multiple comparisons, using SPSS v.14 
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software (Chicago, IL, USA). Differences between the Im-HA group and control group were 
compared at each time point by Mann-Whitney’s U test (qRT-PCR) and unpaired t-test 
(histomorphometry, SAM, the number of macrophages and vessels). Data was expressed as mean ± 
standard deviation (SD). A value of P < 0.05 was accepted as statistically significant.  
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5. Results 
5.1 Histology and Histomorphometry 
      In the histological appearance of the postero-superior synovial membrane and capsule, 
adhesion was observed primarily between the postero-superior synovial fold and the synovial 
membrane around the posterior horn of the medial meniscus after 2 weeks, both in the control and 
the Im-HA groups (Fig. 7b and i). After 4 weeks, the adhesion area extended to the posterior side, 
diminishing the residual joint space, especially in the control group (Fig.7c and j). The adhesion 
area was replaced by fibrous and hypocellular connective tissues after 8 weeks both in the control 
and Im-HA groups. These changes were more dominant in the control group than those in the 
Im-HA group (Fig.7e-g and 7l-n). The anterior synovial membrane and capsule showed similar 
changes compared to the posterior synovial membrane and capsule (Fig. 8 and 9). 
          The length of the postero-superior synovial membrane was significantly longer at 4 to 8 
weeks in the Im-HA group than that of the control group (Fig. 10C). There were no statistical 
differences in the length of the antero-superior (Fig. 10A), antero-inferior (Fig. 10B), 
postero-inferior (Fig. 10D), outside length of the posterior capsule (Fig. 10E), anterior capsular area, 
or posterior capsular area (Fig. 10F) between the two groups.  
         The low sound speed (blue) area gradually decreased and high sound speed area (yellow 
to red) increased with time in the posterior and anterior synovial membrane and capsule in both 
groups (Fig.11 and 12). The average sound speed of the posterior capsule gradually increased in 
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both groups. The average sound speed of the posterior capsule at 2 and 4 weeks in the Im-HA group 
were significantly lower than that in the control group (Fig. 13a and 14A). The anterior capsule 
showed similar changes compared to the posterior synovial membrane and capsule (Fig. 12b and 
13B) 
5.2 Inflammatory conditions 
        CD68 positive cells were mainly located at the surface layer of the synovial membrane 
and the fibrous layer of the capsule at 1 week in both groups (Fig. 15A and H). Positive cells were 
observed in the adhesion area after 2 weeks and gradually disappeared in both groups (Fig. 15B-G 
and I-N). Though the Im-HA group showed similar changes, the number of positive cells were 
fewer than those in the control group. CD68 positive cells at 4 to 8 weeks in the control group were 
significantly higher than that in the Im-HA group (Fig. 16). In double staining of CD68 (red) and 
IL-6 (green), IL-6 were especially observed at the early phase in the control group (Fig. 17A and B), 
which existed around the CD68 positive cells and extended adhesion area of the posterior synovial 
membrane (Fig. 17C). The gene expressions of IL-6 at 2 and 4 weeks (Fig 18A) and IL-1β at 1 
week (Fig 18B) were significantly higher in the control group compared with those in the Im-HA 
group. 
5.3 Fibrotic conditions 
      The gene expressions of SPARC at 1 week (Fig. 19A), TGF-β1 at 1 week and 2 weeks (Fig. 
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19B), COL1a1 at 1 week (Fig. 19C), COL3a1 at 2 weeks (Fig. 19D), and CTGF at 1 week (Fig. 
19E) were significantly higher in the control group compared with those in the Im-HA group. 
5.4 Hypoxic conditions 
     The number of blood vessels in both groups gradually decreased in each area (Fig. 20A-D). 
The number was significantly lower in the Im-HA group at 16 weeks in the antero-superior (Fig. 
19A), at 6, 12, and 16 weeks in the postero-superior (Fig. 20C), and at 16 weeks in the 
postero-inferior areas (Fig. 20D) compared to the control group. There was no significant difference 
in the number of vessels in the antero-inferior area (Fig. 20B). Small vessels were observed in the 
adhesion area, especially in the control group (Fig. 21A and B). The gene expressions of HIF-1α 
and VEGFa at 1 week was significantly higher in the control group (Fig. 22A and B) compared with 
those in the Im-HA group. 
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6. Discussion 
       The present study examined the effects of HMWHA on the synovial membrane and joint 
capsule from immobilized knees in rats. The most important finding of this study was that 
intra-articular HMWHA injections suppressed inflammation, fibrosis, and vascularization in the 
synovial membrane and joint capsule. My results indicate clinical benefits of HMWHA injections 
for prevention of joint contracture.  
       Adhesion and shortening of the synovial membrane is a key to joint contracture and 
induces limitation in the ROM 1,68). The shortening of the synovial membrane was explained by 
atrophy or adhesions of the synovial membrane and the obliteration of joint spaces between the 
synovial membrane and articular cartilage 2). In our previous study, significant shortening of the 
synovial membrane occurred at 2 weeks of immobilization in the posterior capsule 28). Joint 
contracture rapidly progressed until 8 weeks and advanced slowly after 8 weeks of immobilization 
28). Several studies suggested that HA prevent postoperative adhesions 73-75). Subacromial injections 
of HA after arthroscopic rotator cuff surgery tended to produce faster recovery results 73). 
Hyaloglide, a hyaluron-based gel, demonstrated better recovery of finger motion after tenolysis 
surgery of flexor tendons in zone II 74). The postero-superior length of the synovial membrane in the 
control group was significantly shorter compared with the Im-HA group from early to chronic 
phases, but no statistical difference was observed between the two groups in the outside length of 
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the posterior capsule and posterior capsular area. This result suggests that the area of proliferated 
adhesions did not induce an increase in the total capsular area in both groups, and only the inner 
layer (synovial membrane) adhered to the facing capsule. Our data indicate that HMWHA 
injections may prevent adhesion and shortening of the synovial membrane after joint 
immobilization. No statistical difference was observed between the two groups in the 
antero-superior or antero-inferior lengths of the synovial membrane. These results may be related to 
the methods of immobilization in the hyper-flexed position in our study. Because the anterior side 
has motion while walking around.  
        The sound speed of the anterior and posterior synovial membrane and capsule in the 
control group was significantly higher than that in the Im-HA group at the early phase, especially 
around the adhesion area. This result suggests that HMWHA injections decreased the elasticity of 
the synovial membrane and capsule by reducing adhesions in the early experimental periods. The 
sound speed of the control group was higher in this study before 4 weeks compared with our 
previous studies 7,70). These differences may be due to different series of the experiment including 
injection methods. 
         Several prior studies have identified concerns regarding inflammation after joint 
immobilization 29,76). Michelson et al. reported inflammatory changes in the synovial membrane 
after 4 days of immobilization 76). Our previous study showed the genes of pro-inflammatory 
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cytokines such as IL-1α, IL-1β, TNF-β, and IL-6 increased in the capsule after immobilization 
without injection at 1 day and/or 1 week 29) , which were similar to the control group in this study. 
The gene expressions of IL-6 at 2 and 4 weeks and IL-1β at 1 week were significantly lower in the 
Im-HA group compared with that in the control group. These data indicated that HMWHA might 
prevent inflammatory conditions in the synovial membrane and capsule after immobilization. These 
were in agreement with other published reports, which suggested that HMWHA could be an 
anti-inflammatory solution 77-81). HMWHA acted directly on macrophages to inhibit phagocytosis 
and active oxygen formation in chronic inflammation 81) and demonstrated significant decreases of 
IL-1β, IL-6, and macrophage infiltration in the early inflammatory phase in the epidural space and 
around the nerve root in a postlaminectomy rat model 79). Campo et al. reported that HMWHA 
reduces inflammation and cartilage injury in collagen-induced arthritis in mice 80). Roth et al. 
reported that HA inhibited histological signs of acute inflammation and cartilage degeneration, but 
promoted joint swelling, inflammation and cartilage degeneration at 29 days in the experimental rat 
antigen-induced arthritis 82). These contradictory results might be caused by differences in animal 
species, experimental model and/or the molecular weight of HA.  
      Macrophages are critically involved in both the induction and resolution of fibrosis. 
Macrophages produce profibrotic mediators that directly activate fibroblasts, including TGF-β1 
37,83). TGF-β1 is one of the most significant factors in tissue fibrosis 38). Our previous data 
24 
 
demonstrated that the potency of the synovial membrane and capsule to produce TGF-β1 and CTGF 
after immobilization in a rat knee 30). Previous studies have shown strong immunostaining of 
TGF-β1 in frozen shoulder 20), and an increase of TGF-β1 in post-traumatic contracture of human 
elbows 84). Additionally, because a TGF-β response element was found in the CTGF promoter 85), 
CTGF may be a potential downstream mediator for TGF-β signaling in fibroblasts and some of the 
actions of TGFβ1 in wound healing may be due to CTGF induction and action 86). The gene 
expression of CTGF is overexpressed in a large number of fibrotic conditions 87-89). Subcutaneous 
injection of CTGF alone had little effect but co-injection of TGF-β1 and CTGF resulted in 
persistent fibrosis 90). TGF-β1 and CTGF are likely to play an important role in causing and 
maintaining joint contracture 30).  
         It has been shown that expression of SPARC is regulated by TGF-β in several types of 
fibroblast 91). It has also been reported that SPARC regulates the expression and activity of TGF-β 
40). SPARC is a multifunctional glycoprotein that exemplifies the multicellular class of proteins 92). 
Increased production of SPARC has been shown in wound healing, at sites of angiogenesis, and 
during human cancer progression 93-95). SPARC also binds directly to fibrillar collagen type I, III, 
and V, and to basement membrane collagen IV 96-98). Several studies have shown that inhibition of 
SPARC expression decreases inflammation and fibrosis in several animal models 41,43). 
Atorrasagasti et al. showed that SPARC depletion in a mouse genetic model results in protection 
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against liver fibrosis development 41). Socha et al. showed that the kidney damage from 
inflammation and fibrosis resulting from ANG II-induced hypertension is ameliorated in 
SPARC-null mice 43). These data support that SPARC is a mediator of tissue remodeling. However, 
the role of SPARC in the joint capsule after immobilization has been controversial. Importantly, 
HMWHA has been shown to have antifibrotic properties 99,100). Ma et al. reported that HMWHA 
was effective in decreasing pleural fibrosis in a rabbit model 99), and Akeson et al. presented that 
topical HMWHA gel decreased epidural fibrosis in rat laminectomy models 100). The gene 
expressions of SPARC, TGF-β1, and CTGF in the control group increased after immobilization, 
and it was significantly higher compared to the Im-HA group in our study. On the basis of these 
data, HMWHA strongly prevent fibrosis progression, with regulating SPARC and TGF-β1. 
         The major structural collagens of the capsule are collagen types I and III, and the former 
made up 83% of the collagen present 101). Collagen type I is a major component of the capsule 
101,102). Collagen type III is of particular significance in the development and differentiation of 
mesenchymal tissue, and is present in large quantities in tissues requiring high levels of mechanical 
compliance 103) and in wound healing 104). Determination of structural collagens is a key to 
understanding the elastic changes and pathology of the synovial membrane and capsule after 
immobilization 102). Matsumoto et al. reported strong protein expression levels of collagen type I 
and III in immobilized knees in rats like our control model 102). Hildebrand et al. reported increased 
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gene and protein expressions of collagen type I and III in a rabbit knee post-traumatic model 105). 
Shollmeier reported no changes of collagen type I and III expression in a canine immobilized 
shoulder model by IHC 106). In our previous data, the expression of mRNA and protein levels of 
collagen types I and III were not increased after immobilization, which indicated that accumulation 
of the two types of collagen were not the etiology of joint contracture 107). In this study, the gene 
expressions of COL1a1 and COL3a1 in the Im-HA group were significantly lower compared with 
that in the control group. HMWHA may suppress expression of collagen type I and type III. 
However, changes in collagen types I and III in the synovial membrane and capsule after 
immobilization are still controversial. Abnormal cross-linking, such as pentosidine, may play an 
important role for capsular stiffness 108).  
        HIF-1α acts as a master regulator for the expression of genes involved in the hypoxia 
response of most mammalian cells 109-111). It induces the transcription of more than 60 proteins, 
including VEGF and erythropoietin 112). HIF and VEGF signaling is essential for the maintenance 
of vascular density and oxygen supply in tissue hypoxia. Hypoxia has been shown to express 
increased amounts of HIF-1α and HIF-1 target genes in synovial lining cells and articular 
chondrocytes, which aggravate joint inflammation in RA joints 113,114). Previous studies have 
examined joint immobilization induced prolonged inflammation and hypoxia in the joint capsule 29). 
Additionally, there are a few reports examining the role of macrophage-specific HIF-1α in vascular 
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inflammation and remodeling 115,116). Nakamura et al. demonstrated that the macrophage-specific 
HIF-1α plays a crucial role in promoting vascular inflammation and remodeling 116). Therefore, 
HIF-1α is identified as a key player in the pathogenesis of inflammation relting to hypoxia. To the 
best of our knowledge, only one study reported that HA suppressed HIF-1α, which demonstrated 
that early intervention of HA suppressed the expression of HIF-1α in the synovium of the tibiotarsal 
joint in a RA rat model 117). HIF-1α leads to an increased expression of angiogenetic factors such as 
VEGF 112). VEGF is a potent stimulator of vascular angiogenesis, permeability, and remodeling that 
also plays important roles in wound healing and tissue cytoprotection 118). HIF and VEGF signaling 
is essential for the maintenance of vascular density and oxygen supply in tissue with hypoxia. In our 
study, the gene expressions of HIF-1α and VEGFa in the Im-HA group were significantly lower at 1 
week in the posterior capsule. These results showed that HMWHA might suppress HIF-1α, which 
might induce inflammation.  
         Immobilization has been found to decrease the number of blood vessels in the synovial 
membrane and joint capsule, which may be a cause of hypoxia 29,119). However, hypoxic conditions 
induced newly formed blood vessels 120). Tang et al. showed that intra-articular HA injections 
suppressed myofibroblasts and blood vessels in rat knees 48). In our study, the number of blood 
vessels gradually decreased and small blood vessels were observed in the anterior and posterior 
synovial membrane and capsule in both groups, as previously reported 29). Recent studies have 
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found that the degree of hypoxia is associated with the gene expressions of collagen type I and 
α-SMA, and hypoxia induces profibrotic states 121). In addition, the gene expression of SPARC was 
induced by blood vessels close to the lesion and in blood vessels which developed the following 
injury 93). The vascular basement membrane was disrupted and vascular function was enhanced in 
tumors grown in SPARC-null mice 122). These data support that SPARC modulates angiogenesis. 
The number of blood vessels in the posterior synovial membrane and capsule in the control group 
was significantly higher than that in the Im-HA group after 6 weeks. These data suggests that joint 
immobilization induced newly formed blood vessels caused by hypoxia, particularly in the control 
groups. This study showed that immobilization induces hypoxic condition and HMWHA might 
suppress vascularization, which leads to decreasing inflammation and fibrosis. 
         Joint immobilization induced various pathological conditions such as adhesion, 
inflammation, fibrosis, and hypoxia, which caused joint contracture (Fig. 23). HMWHA injections 
suppressed the inflammatory, fibrotic, and hypoxic changes in the capsule after immobilization, and 
prevented adhesion and shortening of the synovial membrane and decreased the elasticity of the 
synovial membrane and capsule as a result (Fig. 24). In clinical situations, ROM restriction by 
capsular contracture is a well recognized postoperative complication of shoulder joint diseases, such 
as rotator cuff tears and recurrent anterior dislocations 123-126). Intra-articular HMWHA injections 
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may be a useful treatment of postoperative joint contracture by suppressing the histological, 
histomorphometric and immunohistochemical changes in the capsule in during early phase. 
  There were several limitations in this study. The study did not assess LMWHA, dose effect, and 
inflammatory response of normal saline injection. Some results show dispersion or variability in my 
data. A possible factor may be sample size. Further study is needed to clarify the effect of HMWHA 
on the synovial membrane and capsule after immobilization, both in animal and human samples. 
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7. Conclusions 
        The present study demonstrated that intra-articular HMWHA injection might be 
beneficial for the treatment of joint contracture by suppressing the inflammatory, fibrotic, and 
hypoxic changes in the capsule after immobilization in the early phase. 
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Figure legends 
Figure 1. Our predicted pathology of frozen shoulder. 
 
Figure 2. Methods of joint immobilization. A: Plastic plate and metal screws. B: Lateral 
photograph of the immobilized knee. Yellow line square indicated the position of a plastic plate. C: 
Protocals of administration. Hyalironan or saline was administered on the day of surgery, and once 
a week afterwards until euthanasia. One week after the final administration, the rats were 
euthanized. Arrow shows the administration of hyaluronan or saline. 
 
Figure 3. Standardized sagittal section of the knee and evaluated areas for the histomorphometry. 
Synovial membrane length of the antero-superior (a), antero-inferior (b), postero-superior (c), 
postero-inferior (d), and outside of the posterior capsule (e) was separately measured.  Anterior 
capsular area (f) and posterior capsular area (g) were also measured.   
Elastica-Masson staining. Scale bar = 1 mm (A and D) and 500 μm (B and C). 
 
Figure 4. A concept Scanning Acoustic Microscope (SAM). A: Schematic illustration of SAM. B: 
Appearance of SAM. Using a single pulse wave instead of continuous waves was applied to 
measure the sound speed of the anterior and posterior synovial membrane (SM), comparing it with 
41 
 
the corresponding light microscopic images. The reflected waveform comprises two reflections at 
the surface and the interface between the tissue and the glass. The thickness and sound speed were 
calculated by Fourier-transforming of the waveform. 
 
Figure 5. Standardized sagittal section of the knee and evaluated areas for SAM. Squares indicate 
resions of analysis by scanning acoustic microscopy in anterior (a) and posterior (b) synovial 
menbrane. Elastica-Masson staining. Scale bar = 1 mm. 
 
Figure 6. Standardized sagittal section of the knee and evaluated areas for α -SMA. a: 
antero-superior, b: antero-inferior, c: postero-superior, d: postero-inferior subdivisions. 
Elastica-Masson staining. Scale bar = 1 mm. 
 
Figure 7. Histological appearance of the posterior synovial membrane and capsule. Changes in the 
histological appearance of the postero-superior area at 1weeks, 2 weeks, 4 weeks, 6weeks, 8 weeks, 
12weeks, and 16 weeks in the control groups (a-g) and in the Im-HA groups (h-n). Adhesion 
(asterisk) was observed primarily between the postero-superior synovial fold and the synovial 
membrane around the posterior horn of the medial meniscus after 2 weeks in the control groups and 
the Im-HA groups. Adhesions were extended especially in the control group. The adhesion area 
(asterisk) was replaced by fibrofatty loose connective tissues. F: Femur, T: Tibia, M: Meniscus, JS: 
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Joint space, Asterisks: Adhesion area. Hematoxylin and Eosin staining. Scale bars = 500 μm. 
 
Figure 8. Histological appearance of the antero-superior synovial membrane and capsule. Changes 
in the histological appearance of the antero-superior area at 1weeks, 2 weeks, 4 weeks, 6weeks, 8 
weeks, 12weeks, and 16 weeks in the control groups (a-g) and in the Im-HA groups (h-n). Adhesion 
was observed primarily after 2 weeks in both groups. The adhesion area was replaced by fibrofatty 
loose connective tissues as with postero-superior area. F: Femur, M: Meniscus, Asterisks: Adhesion 
area. Hematoxylin Eosin staining. Scale bars = 500 μm. 
 
Figure 9. Histological appearance of the antero-inferior synovial membrane and capsule. Changes 
in the histological appearance of the antero-inferior area at 1weeks, 2 weeks, 4 weeks, 6weeks, 8 
weeks, 12weeks, and 16 weeks in the control groups (a-g) and in the Im-HA groups (h-n). Adhesion 
was observed primarily after 2 weeks in both groups. The adhesion area was replaced by fibrofatty 
loose connective tissues as with postero-superior area. T: Tibia, M: Meniscus, Asterisks: Adhesion 
area. Hematoxylin Eosin staining. Scale bars = 500 μm. 
 
Figure 10. Changes in the synovial membrane length and area. The synovial membrane length in 
the antero-superior (A), antero-inferior (B), postero-superior (C), postero-inferior (D), outside 
length of the posterior capsule (E), anterior capsular area (F), and posterior capsular area (G). 
Length of the postero-superior synovial membrane was significantly longer at 4, 6 and 8 weeks in 
the Im-HA group than the control group (C). There were no statistical differences in the length of 
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the antero-superior (A), antero-inferior (B), postero-inferior (D), outside length of the posterior 
capsule (E), anterior capsular area (F), or posterior capsular area (G) between the 2 groups. Data 
were expressed as mean ± SD. * = p < 0.05, ** = p < 0.01, *** = p < 0.005 versus control. 
 
Figure 11. Elastic changes of the posterior synovial membrane. The SAM of the posterior synovial 
membrane (a-n), and graduation color table (o). The low sound speed (blue) area gradually 
decreased and high sound speed area (yellow to red) increased with time in both groups, especially 
in the control groups (a-n). F: Femur, T: Tibia, M: Meniscus, White Arrowheads: posterior 
synovial membrane. 
 
Figure 12. Elastic changes of the anterior synovial membrane. The SAM of the anterior synovial 
membrane (a-n), and graduation color table (o). The low sound speed (blue) area gradually 
decreased and high sound speed area (yellow to red) increased with time in both groups, especially 
in the control groups (a-n). F: Femur, T: Tibia, M: Meniscus, White Arrowheads: anterior synovial 
membrane. 
 
Figure 13. Gradation color images of scanning acoustic microscopy in the posterior and anterior 
SM. a, Posterior SM in 2-week control group. b, Anterior SM in 2-week Im-HA group. c, gradation 
color table. Regions enclosed with a dotted line indicate the SM for calculation. F: Femur, T: Tibia, 
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M: Meniscus 
 
Figure 14. Sound speed of the posterior and antterior synovial membrane. The average sound speed 
of the posterior SM at 1 week to 4 weeks in the control group was significantly higher than that in 
the Im-HA group (A). The average sound speed of the anterior SM at 2 week to 6 weeks in the 
control group was significantly higher than that in the Im-HA group (B). Data were expressed as 
mean ± SD. * = p < 0.05, ** = p < 0.01, *** = p < 0.005 versus control. 
 
Figure 15. Immunohistochemistry of CD68 in the posterior capsule. The immunostaining of CD68 
in the posterior synovial membrane and capsule (A-N). CD68 positive cells were mainly located at 
the surface layer of the synovial membrane and the fibrous layer of the capsule at 1 week in both 
groups (A and H). The positive cells were observed in the adhesion area after 2 weeks and gradually 
disappeared in both groups (B-G, and I-N). JS: Joint space, Black Arrowheads: Positive cells of 
CD68, Asterisks: Adhesion area. Scale bars = 100 μm. 
 
Figure 16. The number of CD68 in the posterior capsule. CD68 positive cells at 4 weeks to 8 weeks 
in the control groups were significantly higher than that in the Im-HA group (G).  
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Figure 17. Double staining of CD68 (red) and IL-6 (green) at 2 weeks in the Im-HA group (B), in 
the control group (A), and high magnification image of figure I (C). In double staining of CD68 
(red) and IL-6 (green), IL-6 especially observed at early phase in the control group, there is little 
visible in the Im-HA group (A and B). IL-6 existed around CD68 positive cells, and the extended 
adhesion area of the posterior synovial membrane (C). Scale bars in figure A and B = 50μm. Scale 
bar in figure C = 200μm, 
 
Figure 18. Inflammatory gene expressions. The gene expression of IL-6 at 2 and 4 weeks (A) and 
IL-1β at 1 week (B) were significantly higher in the control group compared with the Im-HA 
group. Data were expressed as mean ± SD. * = p < 0.05, ** = p < 0.01 versus control. 
 
Figure 19. Fibrotic gene expressions in the posterior capsule. The gene expressions of SPARC, 
TGF-β, COL1a1, COL3a1, and CTGF in the posterior capsule (A)–(E). The gene expressions of 
SPARC at 1 week (A), TGF-β at 1 week and 2 weeks (B), Col1a at 1 week (C), Col3a at 2 weeks 
(D), and CTGF at 1 week (E) were significantly higher in the control group when compared with 
the Im-HA group. Data were expressed as mean ± SD. * = p < 0.05, ** = p < 0.01 versus control. 
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Figure 20. The number of blood vessels. A: antero-superior area, B: antero-inferior area, C: 
postero-superior area, D: postero-inferior area. The number of blood vessels in both groups 
gradually decreased in each area (A-N). The number was significantly lower in the Im-HA group at 
16 weeks in the antero-superior (A), at 6, 12 and 16 weeks in the postero-superior (C), and at 16 
weeks in the postero-inferior areas (D) when compared to the control group. There was no statistical 
difference in the number of vessels in the antero-inferior area (B). Data were expressed as mean ± 
standard deviation. * = p < 0.05, ** = p < 0.01 versus control. 
 
Figure 21. Immunohistochemistry of α-SMA in the postero-superior area at 6 weeks in the 
control group (A) and the Im-HA group (B). Small vessels were observed in the adhesion area 
especially in the control group (A and B). M : Meniscus, Asterisks: Adhesion area. Arrow head : 
Small vessels. Scale bars = 200 μm. 
 
Figure 22. Hypoxic gene expressions in the posterior capsule. 
The gene expression of HIF-1α (A) and VEGFa (B). The gene expression of HIF-1α and 
VEGFa at 1 week was significantly higher in the control group when compared with Im-HA group. 
Data were expressed as mean ± SD. * = p < 0.05 versus control. 
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Figure 23. Schema of joint contracture induced by immobilization. 
Joint immobilization induced adhesion, inflammation, fibrosis, and hypoxia, and decreased HA, 
which caused joint contracture. 
 
Figure 24. Schema of HMWHA effects on immobilized joint. 
HMWHA injection suppressed the inflammatory, fibrotic, and hypoxic changes in the capsule after 
immobilization, and prevented adhesion and shortening of the synovial membrane and decreased 
the elasticity of the synovial membrane and capsule as a result. 
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Table 1 	
Gene Neme	 GenBank　　	 Nucleic acid sequences	
IL-6 	 NM_001008725.3 	 Upstream  gagcccaccaggaacgaaagtc  
Downstream  tgttgtgggtggtatcctctgtgaa  
IL-1β NM_031512.2 	
	
Upstream  tgggcctcaaggggaagaa  
Downstream  tggggaactgtgcagactcaaa  
SPARC	 NM_003118	 Upstream  agaggaggtggtggcggaaaat	
Downstream  gtggcaaagaagtggcaggaaga	
TGF-β1	 NM_000660	 Upstream  aggacctcggctggaagtggat	
Downstream  aggcgcccgggttatgct	
Col1A1	 Z74615	 Upstream  cgagggccaagacgaagacatc	
Downstream  gggcagacgggacagcactc	
Col3A1	 NM_000090	 Upstream  tgaagggcagggaacaact	
Downstream  ccgcataggactgaccaagat	
CTGF	 NM_001901	 Upstream  gaagagaacattaagaagggcaaaaag	
Downstream  ccggcagggtggtggtt	
HIF-1α 	 NM_024359 	 Upstream  gcggctggggacacgat  
Downstream  tttcagaggcaggtaatggagaca  
VEGFa	 NM_031836.2 	
	
Upstream  cgggattgcacggaaactt  
Downstream  gcgcagaccacggctactc  
EF1a1	 NM_175838_ 	 Upstream  tgatgccccaggacacagagact  
Downstream  gataccagcttcaaattccccaacac  
